XML 15 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Income (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Net sales $ 525,321 $ 510,422 $ 1,024,993 $ 996,699
Cost of goods sold 225,220 222,522 453,480 430,217
Gross profit 300,101 287,900 571,513 566,482
Selling, general and administrative expense 195,331 162,256 381,248 333,549
Research and development expense 53,224 52,336 105,165 105,259
Segment profit (loss) 51,546 73,308 85,100 127,674
Interest expense 11,664 12,401 22,641 25,597
Foreign exchange losses, net 865 1,619 2,393 3,060
Other (income) expense, net (8,644) (6,731) (10,044) (13,181)
Income before income taxes 47,661 66,019 70,110 112,198
Provision for income taxes (12,987) (17,454) (15,916) (32,689)
Net income including noncontrolling interests 34,674 48,565 54,194 79,509
Net loss (income) attributable to noncontrolling interests 0 (222) (21) (161)
Net income attributable to Bio-Rad $ 34,674 $ 48,343 $ 54,173 $ 79,348
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 1.22 $ 1.71 $ 1.90 $ 2.81
Weighted average common shares - basic 28,538 28,250 28,516 28,226
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 1.20 $ 1.69 $ 1.88 $ 2.78
Weighted average common shares - diluted 28,868 28,610 28,843 28,582